The Influence of Genetic Variations in the CD86 Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation
Table 5
An analysis of the associations between two genetic factors and risk of aGvHD using the Svejgaard and Ryder method [19].
(a) Factor A (carriers of A alleles for CD86 rs1129055 in recipients) and factor B (possessing the CT60GG (rs3087243 GG) genotype for the CTLA-4 gene in recipients)
aGvHD present
aGvHD absent
A+B+
35
13
A−B+
32
25
A+B−
29
36
A−B−
39
51
Test
OR
95% CI
Comparison
Individual association
(1) A
1.58
0.07
0.97–2.58
(2) B
2.25
0.002
1.35–3.75
(3) ++ versus −+
2.10
0.08
0.92–4.80
A in B-positive
A association
(4) +− versus −−
1.05
0.87
0.55–2.00
A in B-negative
(5) ++ versus +−
3.34
0.003
1.49–7.46
B in A-positive
B association
(6) −+ versus −−
1.67
0.13
0.86–3.27
B in A-negative
(7) +− versus −+
0.63
0.21
0.31–1.29
Differences between A and B association
(8) ++ versus −−
3.52
0.001
1.65–7.35
Combined association
(b) Factor A (carriers for the CD86 rs1129055GG genotype in donors) and factor B (possessing the CT60GG (rs3087243GG) genotype for the CTLA-4 gene in recipients)